The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review.

about

The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review.

Item

http://www.wikidata.org/entity/Q50109832

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

The Impact of Biologics and To ...... Systematic Literature Review.

@en

The Impact of Biologics and To ...... Systematic Literature Review.

@nl

type

Item

label

The Impact of Biologics and To ...... Systematic Literature Review.

@en

The Impact of Biologics and To ...... Systematic Literature Review.

@nl

prefLabel

The Impact of Biologics and To ...... Systematic Literature Review.

@en

The Impact of Biologics and To ...... Systematic Literature Review.

@nl

P1476

The Impact of Biologics and To ...... Systematic Literature Review.

@en

P2093

Blerina Kola

http://www.w3.org/2001/XMLSchema#string

Ernest Choy

http://www.w3.org/2001/XMLSchema#string

Michael Nurmohamed

http://www.w3.org/2001/XMLSchema#string

Paola Accossato

http://www.w3.org/2001/XMLSchema#string

Ryan DeMasi

http://www.w3.org/2001/XMLSchema#string

Sadiq Lula

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic dr

Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data.

Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis.

74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis.

Modifications in lipid levels are independent of serum TNF-α in rheumatoid arthritis: results of an observational 24-week cohort study comparing patients receiving etanercept plus methotrexate or methotrexate as monotherapy.

Infliximab, an anti-TNF-alpha agent, improves left atrial abnormalities in patients with rheumatoid arthritis: preliminary results.

P2888

s40264-017-0628-9

P304

473-488

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S40264-017-0628-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29318514

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease

P932

5938314

http://www.w3.org/2001/XMLSchema#string